Insider Buying: Enovis (NYSE:ENOV) Director Purchases $24,877.60 in Stock

Enovis Corporation (NYSE:ENOV – Get Free Report) Director Angela Lalor acquired 880 shares of the stock in a transaction on Friday, November 13th. The shares were acquired at an average cost of $28.27 per share, for a total transaction of $24,877.60. Following the completion of the transaction, the director directly owned 34,997 shares in the company, valued at $989,365.19. The trade was a 2.58% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Enovis Stock Performance

Shares of ENOV stock opened at $27.19 on Thursday. The stock’s 50-day moving average price is $21.02 and its 200 day moving average price is $23.30. Enovis Corporation has a 52-week low of $16.70 and a 52-week high of $31.67. The stock has a market capitalization of $1.57 billion, a PE ratio of -2.95 and a beta of 1.31. The company has a quick ratio of 1.08, a current ratio of 2.15 and a debt-to-equity ratio of 0.82.

Enovis (NYSE:ENOV – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.77 by $0.11. The business had revenue of $558.73 million during the quarter, compared to analysts’ expectations of $557.12 million. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The company’s quarterly revenue was up 1.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 earnings per share. As a group, equities research analysts forecast that Enovis Corporation will post 3.15 EPS for the current year.

Hedge Funds Weigh In On Enovis

A number of institutional investors and hedge funds have recently bought and sold shares of ENOV. Allworth Financial LP grew its stake in shares of Enovis by 59.7% during the second quarter. Allworth Financial LP now owns 1,744 shares of the company’s stock valued at $36,000 after acquiring an additional 652 shares in the last quarter. Quarry LP increased its holdings in shares of Enovis by 70.9% in the 3rd quarter. Quarry LP now owns 1,682 shares of the company’s stock valued at $31,000 after acquiring an additional 698 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of Enovis by 5,590.5% during the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after purchasing an additional 1,174 shares during the period. Inspire Investing LLC raised its stake in Enovis by 4.9% during the third quarter. Inspire Investing LLC now owns 34,833 shares of the company’s stock worth $636,000 after acquiring an additional 1,631 shares during the period. Finally, Amundi raised its position in shares of Enovis by 2.3% during the 1st quarter. Amundi now owns 74,184 shares of the company’s stock worth $1,688,000 after purchasing an additional 1,677 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

ENOV has been the topic of a number of recent analyst reports. Wall Street Zen raised Enovis from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Citigroup restated a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd. Wells Fargo & Company upped their target price on shares of Enovis from $33.00 to $37.00 and gave the company an “overweight” rating in a report on Friday, November 6th. BTIG Research increased their price target on Enovis from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Finally, UBS Group reissued a “buy” rating and issued a $44.00 target price on shares of Enovis in a research report on Monday, October 5th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $38.62.

View Our Latest Report on ENOV

About Enovis

(Get Free Report)

Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.

Featured Stories

Insider Buying and Selling by Quarter for Enovis (NYSE:ENOV)

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.